BADERC Welcome

Robert E. Gerszten M.D.

Inflammation and Biomarkers in Cardiovascular Disease

Dr. Gerszten’s research efforts focus on understanding the molecular basis of injury responses in cardiovascular disease. His laboratory has incorporated emerging proteomics and metabolomics technologies to help identify novel signals derived from leukocytes, endothelial cells, or from the myocardium. In ongoing translational studies, his group applies these same methodologies directly to samples from well-phenotyped human cohorts to identify candidate biomarkers, returning again to the bench to define functional roles. The research incorporates basic molecular and cell biology, chemistry and mass spectrometry, bioinformatics, all with a foundation in clinical medicine. The overall goal is to identify new metabolites and proteins that mark cardiovascular disease activity, shed insight into disease progression, and provide targets for therapeutic intervention.

Refernce:

Barth MC, Ahluwalia N, Anderson TJ, Hardy GJ, Sinha S, Alvarez-Cardona JA, Pruitt IE, Rhee EP, Colvin RA, Gerszten RE. Kynurenic acid triggers firm arrest of leukocytes to vascular endothelium under flow conditions. J Biol Chem. 2009 May 27. [Epub ahead of print]
Kuhn E, Addona T, Keshishian H, Burgess M, Mani DR, Lee RT, Sabatine MS, Gerszten RE, Carr SA. Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin Chem. 2009 Jun;55(6):1108-17.
Gerszten RE, Sabatine M, Wang TJ. New antibody assays for cardiovascular disease: future tools for the clinical chemist? Clin Chem. 2009 Mar;55(3):404-6.
King VL, Lin AY, Kristo F, Anderson TJ, Ahluwalia N, Hardy GJ, Owens AP 3rd, Howatt DA, Shen D, Tager AM, Luster AD, Daugherty A, Gerszten RE. Interferon-gamma and the interferon-inducible chemokine CXCL10 protect against aneurysm formation and rupture. Circulation. 2009 Jan 27;119(3):426-35.
Lewis GD, Wei R, Liu E, Yang E, Shi X, Martinovic M, Farrell L, Asnani A, Cyrille M, Ramanathan A, Shaham O, Berriz G, Lowry PA, Palacios IF, Ta?an M, Roth FP, Min J, Baumgartner C, Keshishian H, Addona T, Mootha VK, Rosenzweig A, Carr SA, Fifer MA, Sabatine MS, Gerszten RE. Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest. 2008 Oct;118(10):3503-12.
Shaham O, Wei R, Wang TJ, Ricciardi C, Lewis GD, Vasan RS, Carr SA, Thadhani R, Gerszten RE, Mootha VK. Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol Syst Biol. 2008;4:214.
Bloch DB, Wang TJ, Gerszten RE. Novel antibody markers of unstable atherosclerotic lesions. J Clin Invest. 2008 Aug;118(8):2675-7.
Lewis GD, Asnani A, Gerszten RE. Application of metabolomics to cardiovascular biomarker and pathway discovery. J Am Coll Cardiol. 2008 Jul 8;52(2):117-23.
Gerszten RE, Accurso F, Bernard GR, Caprioli RM, Klee EW, Klee GG, Kullo I, Laguna TA, Roth FP, Sabatine M, Srinivas P, Wang TJ, Ware LB. Challenges in translating plasma proteomics from bench to bedside: update from the NHLBI Clinical Proteomics Programs. Am J Physiol Lung Cell Mol Physiol. 2008 Jul;295(1):L16-22. Epub 2008 May 2.
Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, Rifai N, Cannon CP, Gerszten RE, Lee RT. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008 Apr 15;117(15):1936-44.
Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008 Mar 13;452(7184):230-3.
Gerszten RE, Wang TJ. The search for new cardiovascular biomarkers. Nature. 2008 Feb 21;451(7181):949-52.
Kircher MF, Grimm J, Swirski FK, Libby P, Gerszten RE, Allport JR, Weissleder R. Noninvasive in vivo imaging of monocyte trafficking to atherosclerotic lesions. Circulation. 2008 Jan 22;117(3):388-95.






			Robert E. Gerszten M.D. Inflammation and Biomarkers in Cardiovascular Disease Dr. Gerszten’s research efforts focus on understanding the molecular basis of injury responses in cardiovascular disease. His laboratory has incorporated emerging proteomics and metabolomics technologies to help identify novel signals derived from leukocytes, endothelial cells, or from the myocardium. In ongoing translational studies, his group applies these same methodologies directly to samples from well-phenotyped human cohorts to identify candidate biomarkers, returning again to the bench to define functional roles. The research incorporates basic molecular and cell biology, chemistry and mass spectrometry, bioinformatics, all with a foundation in clinical medicine. The overall goal is to identify new metabolites and proteins that mark cardiovascular disease activity, shed insight into disease progression, and provide targets for therapeutic intervention. Refernce: Barth MC, Ahluwalia N, Anderson TJ, Hardy GJ, Sinha S, Alvarez-Cardona JA, Pruitt IE, Rhee EP, Colvin RA, Gerszten RE. Kynurenic acid triggers firm arrest of leukocytes to vascular endothelium under flow conditions. J Biol Chem. 2009 May 27. [Epub ahead of print] Kuhn E, Addona T, Keshishian H, Burgess M, Mani DR, Lee RT, Sabatine MS, Gerszten RE, Carr SA. Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin Chem. 2009 Jun;55(6):1108-17. Gerszten RE, Sabatine M, Wang TJ. New antibody assays for cardiovascular disease: future tools for the clinical chemist? Clin Chem. 2009 Mar;55(3):404-6. King VL, Lin AY, Kristo F, Anderson TJ, Ahluwalia N, Hardy GJ, Owens AP 3rd, Howatt DA, Shen D, Tager AM, Luster AD, Daugherty A, Gerszten RE. Interferon-gamma and the interferon-inducible chemokine CXCL10 protect against aneurysm formation and rupture. Circulation. 2009 Jan 27;119(3):426-35. Lewis GD, Wei R, Liu E, Yang E, Shi X, Martinovic M, Farrell L, Asnani A, Cyrille M, Ramanathan A, Shaham O, Berriz G, Lowry PA, Palacios IF, Ta?an M, Roth FP, Min J, Baumgartner C, Keshishian H, Addona T, Mootha VK, Rosenzweig A, Carr SA, Fifer MA, Sabatine MS, Gerszten RE. Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest. 2008 Oct;118(10):3503-12. Shaham O, Wei R, Wang TJ, Ricciardi C, Lewis GD, Vasan RS, Carr SA, Thadhani R, Gerszten RE, Mootha VK. Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol Syst Biol. 2008;4:214. Bloch DB, Wang TJ, Gerszten RE. Novel antibody markers of unstable atherosclerotic lesions. J Clin Invest. 2008 Aug;118(8):2675-7. Lewis GD, Asnani A, Gerszten RE. Application of metabolomics to cardiovascular biomarker and pathway discovery. J Am Coll Cardiol. 2008 Jul 8;52(2):117-23. Gerszten RE, Accurso F, Bernard GR, Caprioli RM, Klee EW, Klee GG, Kullo I, Laguna TA, Roth FP, Sabatine M, Srinivas P, Wang TJ, Ware LB. Challenges in translating plasma proteomics from bench to bedside: update from the NHLBI Clinical Proteomics Programs. Am J Physiol Lung Cell Mol Physiol. 2008 Jul;295(1):L16-22. Epub 2008 May 2. Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, Rifai N, Cannon CP, Gerszten RE, Lee RT. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008 Apr 15;117(15):1936-44. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008 Mar 13;452(7184):230-3. Gerszten RE, Wang TJ. The search for new cardiovascular biomarkers. Nature. 2008 Feb 21;451(7181):949-52. Kircher MF, Grimm J, Swirski FK, Libby P, Gerszten RE, Allport JR, Weissleder R. Noninvasive in vivo imaging of monocyte trafficking to atherosclerotic lesions. Circulation. 2008 Jan 22;117(3):388-95.